CN Patent

CN111491635A — 包含墨蝶呤的药物组合物及其用途

Assigned to PTC Therapeutics MP Inc · Expires 2020-08-04 · 6y expired

What this patent protects

本发明特点是包含墨蝶呤或其药学上可接受的盐和/或共晶的药物组合物，以及用这样的组合物治疗四氢生物蝶呤相关的病症(例如四氢生物蝶呤缺乏或苯丙酮尿症)的方法。

USPTO Abstract

本发明特点是包含墨蝶呤或其药学上可接受的盐和/或共晶的药物组合物，以及用这样的组合物治疗四氢生物蝶呤相关的病症(例如四氢生物蝶呤缺乏或苯丙酮尿症)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111491635A
Jurisdiction
CN
Classification
—
Expires
2020-08-04
Drug substance claim
No
Drug product claim
No
Assignee
PTC Therapeutics MP Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.